Gerresheimer AG/€GXI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gerresheimer AG
Gerresheimer AG is a prominent player in the healthcare and life sciences industry, specializing in the production of glass and plastic products for pharmaceutical and cosmetic packaging. The company’s key offerings include pharmaceutical vials, prefillable syringes, glass and plastic packaging for drugs, as well as delivery systems for the safe administration of medications. Founded in 1864, Gerresheimer has evolved into a global entity with headquarters in Düsseldorf, Germany, and operates manufacturing sites in Europe, the Americas, and Asia. Its strategic strength lies in a broad product portfolio and advanced technical expertise, enabling it to cater to the stringent requirements of its diverse clientele in the healthcare sector. The company’s comprehensive geographic footprint and commitment to innovation bolster its competitive position in the market.
- Ticker
- €GXI
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 13,301
- Headquarters
- Düsseldorf, Germany
- Website
- www.gerresheimer.com
Gerresheimer AG Metrics
BasicAdvanced
€1.1B
-
-€11.75
0.45
-
Price and volume
Market cap
€1.1B
Beta
0.45
52-week high
€33.98
52-week low
€14.90
Average daily volume
160K
Financial strength
Current ratio
1.069
Quick ratio
0.295
Long term debt to equity
1.616
Total debt to equity
2.367
Interest coverage (TTM)
0.46%
Profitability
EBITDA (TTM)
323.152
Gross margin (TTM)
20.96%
Net profit margin (TTM)
-17.51%
Operating margin (TTM)
1.65%
Effective tax rate (TTM)
-6.19%
Revenue per employee (TTM)
€170,000
Management effectiveness
Return on assets (TTM)
0.52%
Return on equity (TTM)
-32.35%
Valuation
Price to revenue (TTM)
0.476
Price to book
1.16
Price to tangible book (TTM)
-22.36
Price to free cash flow (TTM)
-360.541
Free cash flow yield (TTM)
-0.28%
Free cash flow per share (TTM)
-0.089
Growth
Revenue change (TTM)
15.64%
Earnings per share change (TTM)
-818.93%
3-year revenue growth (CAGR)
6.76%
10-year revenue growth (CAGR)
5.94%
3-year earnings per share growth (CAGR)
55.79%
10-year earnings per share growth (CAGR)
12.91%
What the Analysts think about Gerresheimer AG
Analyst ratings (Buy, Hold, Sell) for Gerresheimer AG stock.
Analyst projections of the future price of Gerresheimer AG stock.
Bulls say / Bears say
Second-quarter adjusted EBITDA rose more than 50% from the first quarter, and management expects a stronger second half. This points to a possible operational recovery after a weak start to 2026. (Reuters)
Demand for drug-delivery devices is supporting growth in the Containment & Delivery business: first-half revenue and adjusted EBITDA both increased year on year. That offers a source of strength while other packaging lines struggle. (Gerresheimer)
The planned sale of Centor and Primary Packaging Plastics for an enterprise value of about €1.5 billion could materially reduce debt. Alongside a transformation programme targeting €50 million to €70 million of annual EBITDA improvements, it may strengthen the remaining business. (Reuters, Gerresheimer)
First-half adjusted EBITDA fell to €168 million from €210.4 million a year earlier, as weaker moulded-glass performance and lower demand for injection vials weighed on results. The second-quarter rebound still left revenue and earnings below the prior-year quarter. (Reuters)
Gerresheimer cut its 2026 margin outlook in June and forecast negative free cash flow of €50 million to €100 million. Continued cash burn could limit room to invest and makes delivery of the recovery more important. (Reuters)
Accounting investigations delayed the company’s financial results, and BaFin opened audits of its statements. The restatements and continuing regulatory scrutiny add uncertainty to reporting credibility and may distract management. (Reuters, Packaging News Daily)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Gerresheimer AG Financial Performance
Revenues and expenses
Gerresheimer AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Gerresheimer AG
AllUSDEURGBP
Fund name | Fund size | €GXI weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.06% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.06% |
Vanguard Germany All Cap£VGER | €258M | 0.05% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.